KRAS and cancer: Consistent with the mechanism of action, we found that KRAS WT–amplified cell lines show a clearly reduced sensitivity to the RAS “ON” clinical compound RMC-6236 and the tool compound RMC-7977 and they are the least sensitive cell lines among the diverse KRAS-mutant and KRAS WT–amplified cell lines that were tested in a large cancer cell line panel (18, 39).